News > Biological E. gets DCGI nod for Pneumococcal Conjugate Vaccine
Biological E. gets DCGI nod for Pneumococcal Conjugate Vaccine
17/12/2022 08:44 AM | Click to read full article
Vaccine maker Biological E., on Friday, said its 14-valent paediatric Pneumococcal Conjugate Vaccine against Streptococcus pneumoniae infection has received approval from the DCGI for manufacture and commercialisation in India. BE said its PCV14 is comparable in terms of serotype coverage for infants to the two globally approved pneumococcal conjugate vaccines Prevenar13 and Merck’s Vaxneuvance.